Last reviewed · How we verify
CDP870
CDP870 is a pegylated TNF-alpha inhibitor that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses.
CDP870 is a pegylated TNF-alpha inhibitor that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses. Used for Rheumatoid arthritis, Crohn's disease, Psoriatic arthritis.
At a glance
| Generic name | CDP870 |
|---|---|
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
CDP870 (certolizumab pegol) is a TNF-alpha antagonist composed of a humanized anti-TNF monoclonal antibody fragment conjugated to polyethylene glycol (PEG). The pegylation increases the drug's half-life and reduces immunogenicity while maintaining its ability to bind TNF-alpha and prevent its interaction with TNF receptors on immune cells, thereby suppressing inflammatory signaling.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Psoriatic arthritis
- Ankylosing spondylitis
Common side effects
- Infection (including serious infections)
- Injection site reactions
- Upper respiratory tract infection
- Headache
- Tuberculosis reactivation risk
Key clinical trials
- A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- Lipids, Inflammation, and CV Risk in RA
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery (PHASE2)
- A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (PHASE2)
- The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CDP870 CI brief — competitive landscape report
- CDP870 updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI